Eli Lilly (LLY) Equity Average (2009 - 2026)

Eli Lilly (LLY) has reported Equity Average for 18 consecutive years, with $28.9 billion the latest figure, recorded in Q1 2026.

• Equity Average for Q1 2026 came in at $28.9 billion, up 3082.08% year-over-year; the trailing twelve-month figure through Mar 2026 was $28.9 billion (up 3082.08% YoY), and the FY2025 annual result was $13.4 billion, up 1067.87% from the prior year.
• Equity Average was $28.9 billion for Q1 2026 at Eli Lilly, up from $25.2 billion in the prior quarter.
• Over five years, Equity Average peaked at $28.9 billion in Q1 2026 and troughed at -$4.3 billion in Q3 2022.
• Average Equity Average over 5 years is $2.0 billion, with a median of -$1.5 billion recorded in 2023.
• Year-over-year, Equity Average plunged 311.17% in 2022 and surged 3176.62% in 2025.
• Over 5 years, Equity Average stood at -$2.1 billion in 2022, then gained by 27.27% to -$1.5 billion in 2023, then jumped by 46.45% to -$818.8 million in 2024, then soared by 3176.62% to $25.2 billion in 2025, then gained by 14.58% to $28.9 billion in 2026.
• Per Business Quant data, the three most recent Equity Average figures were $28.9 billion in Q1 2026, $25.2 billion in Q4 2025, and $11.9 billion in Q3 2025.